Table A2.

Correlation of B7-H1 Expression by Tumor Cells With Tumor Regression Following MDX-1106 Therapy

Patient No.	Diagnosis	MDX-1106 Dose (mg/kg)	Biopsy Site	Biopsy Pre-/Post-Therapy	B7-H1 Staining Pattern*	Clinical Response
0006	NSCLC	0.3	Pleural fluid	Pre-	Membranous	NR
2014	CRPC	3.0	Pelvic LN	Pre-	Negative	NR
			Inguinal LN	Post-	Negative
3019	Melanoma	10.0	Axillary LN	Pre-	Membranous	PR
			Axillary LN	Post-	Membranous
3021	Melanoma	10.0	Parotid gland	Pre-	Membranous	MXR
4025	CRPC	10.0	Epidural mass #1	Post-	Cytoplasmic	NR
			Epidural mass #2	Post-	Cytoplasmic
4033	RCC	10.0	Renal primary	Pre-	Membranous	PR
			Tumor thrombus	Pre-	Membranous
4036	Melanoma	10.0	Subcutaneous	Pre-	Cytoplasmic	NR
4038	Melanoma	10.0	Brain	Pre-	Cytoplasmic	NR
4039	Melanoma	10.0	Small bowel	Pre-	Negative	NR
			Intra-abdominal mass	Pre-	Cytoplasmic

Abbreviations: MDX-1106, anti–programmed death-1 monoclonal antibody; NSCLC, non–small-cell lung cancer; NR, no response; CRPC, castrate-resistant prostate cancer; LN, lymph node; PR, partial response; MXR, mixed response; RCC, renal cell carcinoma.

^*Determined by immunohistochemistry.